PLX

2.73

2.25% 0.06

Dopo l'orario di chiusura: 2.70 -0.03 -1.10%

Protalix BioTherapeutics Inc. (PLX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Forum Previsione Frazionamento azionario

Precedente Chiudi:

$2.67

Aprire:

$2.66

Volume 24 ore:

782.27K

Relative Volume:

1.15

Capitalizzazione di mercato:

$219.96M

Reddito:

$52.74M

Utile/perdita netta:

$-6.60M

Rapporto P/E:

-32.31

EPS:

-0.0845

Flusso di cassa netto:

$-13.63M

1 W Prestazione:

+4.20%

1M Prestazione:

+10.08%

6M Prestazione:

-5.86%

1 anno Prestazione:

+61.54%

Intervallo 1D:

$2.64

$2.735

Intervallo di 1 settimana:

$2.595

$2.735

Portata 52W:

$1.60

$3.19

Protalix BioTherapeutics Inc. Stock (PLX) Company Profile

Nome

Protalix BioTherapeutics Inc.

Settore

Healthcare (1069)

Industria

Biotechnology (595)

Telefono

972 4 988 9488

Indirizzo

2 Snunit Street, Science Park PO Box 455, Karmiel

Dipendente

190

Cinguettio

@Protalix_Bio

Prossima data di guadagno

2026-08-12

Ultimi documenti SEC

PLX's Discussions on Twitter

Compare PLX vs VRTX, REGN, ARGX, MRNA, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
PLX Protalix BioTherapeutics Inc.	2.73	215.13M	52.74M	-6.60M	-13.63M	-0.0845
VRTX Vertex Pharmaceuticals Inc	514.56	132.08B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	793.26	83.15B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	984.04	62.71B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	136.62	54.14B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	203.35	44.51B	742.00K	-1.37B	-1.07B	-7.0731

Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2020-06-08	Reiterato	H.C. Wainwright	Buy
2017-04-17	Reiterato	Rodman & Renshaw	Buy
2016-04-04	Iniziato	Rodman & Renshaw	Buy
2015-04-23	Aggiornamento	Jefferies	Hold → Buy
2014-11-12	Reiterato	R. F. Lafferty	Buy
2014-01-24	Iniziato	R. F. Lafferty	Buy
2012-05-02	Downgrade	Canaccord Genuity	Buy → Hold
2012-05-02	Reiterato	Oppenheimer	Outperform
2012-04-30	Downgrade	Auriga	Buy → Hold
2011-10-13	Iniziato	Morgan Joseph	Hold
2011-03-17	Downgrade	WBB Securities	Strong Buy → Buy
2010-11-09	Reiterato	Oppenheimer	Outperform
2010-10-14	Reiterato	UBS	Buy
2009-12-02	Reiterato	Hapoalim	Outperform
2009-09-22	Iniziato	Canaccord Adams	Buy
2009-09-02	Iniziato	Hapoalim	Outperform
2008-12-01	Reiterato	Oppenheimer	Outperform
2008-03-11	Iniziato	UBS	Buy
2007-11-20	Iniziato	CIBC Wrld Mkts	Sector Outperform

Mostra tutto

Protalix BioTherapeutics Inc. Borsa (PLX) Ultime notizie

Sep 09, 2026

Director at Protalix (NYSE: PLX) gets options expiring 2036 plus 8,500 RSUs - Stock Titan

Sep 09, 2026

PLX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $12 - GuruFocus

Sep 09, 2026

Sep 08, 2026

Protalix BioTherapeutics Insider Bar-Shalev Amos Receives 25,500 Derivative Securities on September 3, 2026 - Kalkine Media

Sep 08, 2026

Protalix BioTherapeutics (AMEX: PLX) Grants 25,500 Derivative Securities to Insider Forster Eliot - Kalkine Media

Sep 08, 2026

Protalix (NYSE: PLX) sets CEO equity to 3-year vesting, change-in-control terms - Stock Titan

Sep 04, 2026

Yaron Naos awarded new equity at Protalix BioTherapeutics (PLX) - Stock Titan

Sep 04, 2026

Director at Protalix BioTherapeutics (PLX) gets new options and stock units - Stock Titan

Sep 04, 2026

Protalix (PLX) awards Amos Bar‑Shalev new 3‑year equity grant - Stock Titan

Sep 04, 2026

Aug 20, 2026

Zacks Research Issues Pessimistic Outlook for PLX Earnings - MarketBeat

Aug 20, 2026

Aug 19, 2026

Protalix (PLX) Q2 2026 Earnings Call Transcript - The Globe and Mail

Aug 19, 2026

Protalix (PLX) Q2 2026 Earnings Call Transcript - The Motley Fool

Aug 19, 2026

Aug 16, 2026

Protalix BioTherapeutics (NYSEAMERICAN:PLX) Advances Plant-Cell Protein Programs - Kalkine Media

Aug 16, 2026

Aug 13, 2026

Protalix BioTherapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance

Aug 13, 2026

PLX: Elfabrio Estimates Up - Yahoo Finance

Aug 13, 2026

Aug 12, 2026